SCHEMBL2267386

SCHEMBL2267386

[c]1cccc(-n2cccn2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 5/20 0.46
NOTUM Q6P988 1/20 0.40
LMNA P02545 3/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
G6PD P11413 1/20 0.37
MAPK1 P28482 3/20 0.37
NPC1 O15118 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 2/20 0.36
GLA P06280 1/20 0.36
GRM5 P41594 3/20 0.35
HTT P42858 2/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
MAPK10 P53779 1/20 0.33
TDO2 P48775 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL199306 0.73 ALDH1A1 (0.65) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL16834749 0.72 CYP2A6 (0.41) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL29115893 0.72 KDM4E (0.58) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL534171 0.72 KDM4E (0.44) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL31519065 0.71 ALDH1A1 (0.63) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL28812535 0.71 ALDH1A1 (0.63) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL173802 0.69 KDM4E (0.50) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL29635627 0.69 KDM4E (0.50) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL15363768 0.68 LMNA (0.49) KDM4EALDH1A1NOTUMLMNAKMT2A
SCHEMBL6482737 0.68 ALDH1A1 (0.48) KDM4EALDH1A1NOTUMLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164458-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 CN claimed
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 US claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
US-9067930-B2 2-oxo-piperidinyl derivatives UCB PHARMA, S.A. (BE) 2015-06-30 US claimed
EP-2766353-B1 2-OXO-PIPERIDINYL DERIVATIVES UCB PHARMA SA (BE) 2015-06-17 EP claimed
US-20150011526-A1 2-Oxo-Piperidinyl Derivatives UCB BIOPHARMA SPRL (BE) 2015-01-08 US claimed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP claimed
EP-2766353-A1 2-OXO-PIPERIDINYL DERIVATIVES UCB Pharma, S.A. (BE) 2014-08-20 EP claimed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 US claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
EP-2688886-A1 AZOLE COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2014-01-29 EP claimed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP claimed
WO-2013053725-A1 2-OXO-PIPERIDINYL DERIVATIVES UCB PHARMA, S.A. (BE) 2013-04-18 WO claimed
WO-2012129338-A1 AZOLE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-09-27 WO claimed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO claimed
CN-113164458-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 CN disclosed
US-9962377-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors TAKEDA GMBH (DE) 2018-05-08 US disclosed
WO-2005085225-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed
CN-1151147-C Indole derivatives as 5 -HT receptor antagonist ʷ��˿�������ȳ�ķ���޹�˾ 2004-05-26 CN disclosed
CN-1179156-A Indole derivatives as 5-HT receptor antagonists SMITHKINE BEECHAM PLC (GB) 1998-04-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187553-A1 Azole Compounds as PIM Inhibitors PIM1, PIM3, PIM2 KDM4E 521/4885ALDH1A1 467/4885NOTUM 2462/4885
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 KDM4E 539/4885ALDH1A1 502/4885NOTUM 2149/4885
US-20150011526-A1 2-Oxo-Piperidinyl Derivatives CYP3A4, CYP2C19, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDM4E 1639/4885ALDH1A1 816/4885NOTUM 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.